Pfizer and Saama Technologies will work together to develop and deploy an artificial intelligence (AI) powered analytical tool geared toward clearing many of the obstacles faced by study data managers and monitors. The Saama Life Science Analytics Cloud (LSAC) platform will aggregate, analyze, model and predict data via'deep learning'. Pfizer's role is to provide the required clinical data and domain knowledge to train Saama models to obtain the accuracy needed. Demetris Zambas, VP and head of data monitoring and management at Pfizer, told Outsourcing-Pharma that Saama was invited to work with his company on the AI project after a'hackathon', in which a number of companies competed with each other. Saama initially was invited to participate based on their core competencies.